BIIB News Alert Biogen Idec Inc (BIIB) 340.89 12/25/2014 13:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 340.89 $BIIB

Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 340.89 (+5.13), VNDA: 14.69 (+1.11), SHPG: 209.29 (+0.07), NVS: 93.91 (+0.66)

Stock Market News for December 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:10AM CST
Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
KMI: 42.01 (+0.10), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), MON: 120.97 (-1.70), AMGN: 160.67 (+3.15), XOM: 93.78 (-0.81), BA: 131.24 (+1.21), SLB: 87.06 (-0.26), CELG: 109.60 (+3.48), LYB: 81.31 (-0.89), REG: 64.30 (-0.04), DD: 74.79 (-0.40), CVX: 113.47 (-0.48), OXY: 82.24 (-0.66), PX: 131.74 (-0.35), DOW: 46.01 (+0.03)

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)

Why I Expect The Biotech Sell-Off To Continue Into 2015
Sammy Pollack - at Seeking Alpha - Wed Dec 24, 7:08AM CST

BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), AMGN: 160.67 (+3.15), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 4.69% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:44PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $328.68 to a high of $353.79. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $337.71 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 340.89 (+5.13)

Biogen Idec Falls 4.69% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Dec 23, 3:43PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $328.68 to a high of $353.79. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $337.71 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 340.89 (+5.13)

Biogen Idec reports January 28
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:21PM CST

BIIB: 340.89 (+5.13)

Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015
Business Wire - Tue Dec 23, 3:01PM CST
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2014 financial results on Wednesday, January 28, 2015, before the financial markets open.
BIIB: 340.89 (+5.13)

Fresh Milestones For Dow, S&P 500 But Biotechs Hit
at Investor's Business Daily - Tue Dec 23, 1:48PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, but the Nasdaq lagged as biotech stocks sold off hard. The Dow added 0.6%, with about one-third of its components up 1% or more. The S&P 500 rose 0.4% and the Nasdaq...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), NOAH: 20.44 (-1.00), BIDU: 230.98 (-2.18), CALM: 42.45 (-1.73), ABG: 77.12 (+0.43), FLT: 149.17 (-0.93), REGN: 400.12 (+6.07)

Biotech Stocks Are Falling: 3 Top Stocks to Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 12:41PM CST
Source: Celgene Corp. Biotechnology stocks have been one of the market's darlings over the past year. The iShares Nasdaq Biotechnology ETF  (NASDAQ: IBB) has roughly doubled the S&P 500's return over the past 5 weeks. Today though, the ETF is...
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)

Toys, Department Stores Rock, But Biotechs Tumble
at Investor's Business Daily - Tue Dec 23, 11:06AM CST
The euphoria over third-quarter GDP growth of 5% evaporated Tuesday morning, leaving stocks trading mixed at midday, with the Nasdaq leading other indexes off their best levels. The Nasdaq was off 0.1% ,the S&P 500 rose 0.3% and the Dow Jones...
HAS: 55.25 (+0.03), BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), M: 64.26 (+0.22), CELG: 109.60 (+3.48), DDS: 122.53 (+0.53), ESRX: 85.48 (-0.40), MAT: 30.22 (-0.16), GILD: 91.29 (+1.84), JCP: 6.50 (-0.24), ALXN: 181.96 (+3.09), ABBV: 66.21 (+1.86)

Indexes Turn Mixed On Data; Celgene Dives
at Investor's Business Daily - Tue Dec 23, 9:43AM CST
Stocks backed off early gains and were mixed early Tuesday as investors wrestled through a jumble of economic news. The Dow Jones industrial average rose 0.4% and the S&P 500 added 0.2% as both indexes reached new highs. The Nasdaq shed its early...
DDS: 122.53 (+0.53), BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), ABG: 77.12 (+0.43), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)

Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 340.89 (+5.13), OREX: 5.98 (+0.01), AMGN: 160.67 (+3.15)

Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), GHDX: 32.44 (+1.32)

Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:55PM CST
Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), ABBV: 66.21 (+1.86)

Biogen Idec to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 22, 3:01PM CST
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 12, 2015 at 3:30 p.m. PT, 6:30 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 340.89 (+5.13), JPM: 62.48 (unch)

Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:20PM CST
Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion for continuous oral treatment with Revlimid.
BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)

Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:10PM CST
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded use.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), ABBV: 66.21 (+1.86)

Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)

Roche Loses A Little Luster Before Year-End
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 1:45PM CST

BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading